|
|
Identifying Needs and Opportunities to Improve Clinical Outcomes in the Identification, Characterization, and Management of Low-Grade Serous Ovarian Cancer
Target Audience
This activity is designed to meet the educational needs of oncologists, obstetrician/gynecologists, gastroenterologists, and primary care physicians to ensure confidence in the diagnosis, characterization, and management of low-grade serous ovarian cancer, including through enrollment in ongoing clinical trials.
Program Overview
This enduring educational activity will provide insight into evidence-based approaches for clinical and pathological assessment of patients with d... |
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 1
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 2
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). Multicancer early detection (MCED) is an emerging form of blood-based testing that utilizes cancer biomarkers in the blood to screen for multiple cancers simultaneously (ACS, 2024). Currently, numerous clinical trials are investiga... |
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 3
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States (ACS, 2024; Pinsky & Berg, 2012; USPSTF, 2024). Multicancer early detection (MCED) is a novel form of blood-based ca... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 1
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 2
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 3
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Improving Equity in Endometrial Cancer Care and Treatment: Accelerating Change to Improve Patient Outcomes in Rural and Underserved Communities
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
In rural and underserved communities, disparities in incidence, treatment, and prognosis are pervasive among women with endometrial cancer. Key factors contributing to these gaps include limited access to oncology specialty care and lack of familiarity with current therapeut... |
|